RE:Bloom Burton: CZO listed as a presenting company...Bloom Burton was CZO's advisor for the merger and now CZO is invited to present at its conference. US$26.49 billion market cap Raymond James was AEZS's advisor for the merger. Will they be involved with the newly merger company providing analyst coverage? H.C. Wainwright's target for AEZS was US$15 last we saw.
As the new diagnostic deal is announced with pediatric data and a filing for pediatric approval is launched in the US and Europe and as AEZS's two lead pipeline programs targeting C$7 billion in total markets approach human trials and as PGX potentially reaches the decision point for mass industrialization in the next six months along with other developments in CZO's pipeline is CZO headed for coverage from a number of analysts while on NASDAQ?